CURRICULUM VITAE

PERSONAL DATA

Surname, Name	**JERÓNIMO, CARMEN DE LURDES FONSECA**
Date of birth	02-06-1972
Citizenship	Portuguese
Marital status	married
E-Mail	Carmenjeronimo@ipoporto.min-saude.pt cljeronimo@icbas.up.pt
Mailing Address	Portuguese Oncology Institute Research Center/Dept of Genetics Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal Phone: + 351 22 508 4000 (ext: 5006) Fax: + 351 22 508 4016
Languages	Portuguese, English

ACADEMIC DEGREES

PHD IN BIOMEDICAL SCIENCES (Cancer genetics)	October /1997- October /2001 PhD student of the Program in Basic and Applied Biology (GABBA), at the Abel Salazar Institute of Biomedical Sciences of the University of Porto.' with the PhD thesis entitled **"Molecular detection of prostate cancer"**. Laboratory research work at Johns Hopkins University School of Medicine; Head & Neck Cancer Research Division. Baltimore - USA (Supervisor: David Sidransky, MD) & at the Department of Pathology; Portuguese Oncology Institute - Porto (Supervisor: Carlos Lopes, MD, PhD)
MSC DEGREE IN ONCOLOGY	October/1995 - February/1998 Abel Salazar Institute of Biomedical Sciences of the University of Porto & The Portuguese Oncology Institute – Porto with the thesis entitled **"Transitional cell carcinoma of the Bladder: expression of p53, bcl-2, nm23, CD44s, CD44v6, and BL2-10D1 and their** relation to histologic grade and stage".
BSC DEGREE IN BIOLOGY	September/1990 – September /1994 Faculty of Sciences of the University of Porto.

PROFISSIONAL EXPERIENCE

HEAD OF CANCER EPIGENETICS GROUP (RESEARCH ASSISTANT)	
July 2009 - current	Research in cancer genetics and epigenetics Research Center of Portuguese Oncology Institute-Porto (CI-IPOP)
GUEST ASSOCIATE PROFESSOR	
September 2009 – Current	Teaching activity & supervision of Post-graduated students Departament of Pathology and Molecular Imunology – ICBAS-University of Porto
GUEST ASSISTANT PROFESSOR	
June 2006 – August 2009	Teaching activity & supervision of Post-graduated students Departament of Pathology and Molecular Imunology – ICBAS-University of Porto
RESEARCH ASSOCIATE	
October 2004 - current	Research in cancer genetics and epigenetics Research Centre of Portuguese Oncology Institute-Porto (CI-IPOP)
ASSISTANT PROFESSOR	
September 2004 – June 2009	Teaching activity Fernando Pessoa University – School of Health Sciences
POSTDOCTORAL FELLOW	
October /2001 – September/2004	Post-doctoral project entitled "Detection of neoplastic cells by DNA-based technology in clinical samples obtained from non-invasive or minimal invasive methods" at Departments of Genetics and of Pathology, Portuguese Oncology Institute -Porto. & "Visiting Scientist" at Head & Neck Cancer Research Division, Johns Hopkins University, Baltimore, MD, USA.

TEACHING ACTIVITY

1. UNDERGRADUATION COURSES

1.1. TEACHING ACTIVITY TO UNDERGRADUATE STUDENTS AT THE SCHOOL OF HEALTH SCIENCES OF FERNANDO PESSOA UNIVERSITY

YEAR	UNIT	COURSE
2007/2008	Histology and Embriology	Clinical Pathology and Public Health
	Medical Genetics	Medical Dentistry
	Molecular Genetics	Pharmacy
2006/2007	Histology and Embriology	Clinical Pathology and Public Health
	Medical Genetics	Medical Dentistry
2005/2006	Histology and Embriology I	Clinical Pathology and Public Health

	Histology and Embriology II	Physiotherapy
		Speech and Language Therapy
2004/2005	Histology and EmbriologyI	Physiotherapy
	Histology and EmbriologyII	Speech and Language Therapy
	Histology and Embriology	Medical Dentistry

1.2. SUPERVISION OF MONOGRAPHIES FOR APPLICATION TO BSC DEGREE

YEAR	TITLE	STUDENT	COURSE
2007/2008	Renal Carcinoma: incidence rate in North of Portugal	Monique Cruz	Clinical Pathology and Public Health
2007/2008	Evaluation of immunoexpression and the methylation levels of MDR1 promotor region in prostatic tissue	Inês Moura	Clinical Pathology and Public Health
2005/2006	Prostate cancer biomarkers	Vítor H. P. Rodrigues	Clinical Pathology and Public Health

1.3. TEACHING ACTIVITY TO UNDERGRADUATE STUDENTS AT OTHER UNIVERSITIES

- Unit of Pathology of the Medical Course of Institute of Biomedical Sciences Abel Salazar – University of Porto (since 2002/2003): Epigenetics and Cancer - prostate cancer
- Module of Oncobiology of the BSc course on Applied Biology of University of Minho (2002/2003): Prostate cancer

2. POST-GRADUATION COURSES

- Module of "Epigenetics and Cancer ", Ph.D. program in Molecular Medicine and Oncobiology, University of Porto – Coordinator and teacher (since 2007)
- Module of "Technologies of laboratorial diagnosis in Oncology", M.Sc. course in Oncology, University of Porto – Coordinator and Teacher (Since 2007)
- Module of "Oncobiology ", M.Sc. course in Biochemistry, University of Porto – Teacher (since 2007)
- Module of "Biopathology", M.Sc. course in Oncology, University of Porto –Teacher (Since 1998)
- Module of "Prostate Cancer", M.Sc. course in Molecular Medicine and Oncology, University of Porto – Coordinator and Teacher (2002/2003 to 2005/2006)

RESEARCH ACTIVITY

1. SUPERVISION OF UNDERGRADUATE PROJECTS

1.1. "Avaliação da hipermetilação do gene CDH1 em adenocarcinoma da próstata e sua correlação com a imunoexpressão da caderina-E (Evaluation of hipermethylation of CDH1 in prostate adenocarcinoma and its correlation with E-cadherin expression)", Pamela Mónica D. T. de Jesus, B.Sc. in Biology, School of Sciences, University of Porto, 2001.

1.2. "Estudo da hipermetilação do gene RARβ2 no cancro da próstata (Study of hipermethylation of RARβ2 in prostate cancer ", Luzia Manuela Lima Teixeira, B.Sc. in Biochemistry, School of Sciences, University of Porto, 2002.

1.3. "Alterações epigenéticas do gene CDH1 em carcinoma da mama: aplicação diagnostica (Epigenetic alterations of CDH1 in breast câncer: clinical application ", Maria Conceição Martins, B.Sc. in Anatomic Pathology, Cytology and Tanatology, School of Health Technologies of Oporto, 2002.

1.4. "Análise do padrão de metilação de diversos genes em neoplasias vesicais (Screening of the methylation pattern of several genes in vesical neoplasms)", Liliana da Silva Matos, B.Sc. in Applied Biology, University of Minho, 2006.
1.5. "Quantificação dos níveis de hipermetilação do gene RARβ2em adenocarcinoma da próstata (Quantification of the methylation levels of RARβ2 in prostate câncer)", Vítor Hugo Pereira Rodrigues, B.Sc. in Clinical Pathology and Public Health, Fernando Pessoa University - Porto, 2006.

2. SUPERVISION OF GRADUATE PROJECTS

2.1. **Supervisor of the Ph.D. project** "Development of epigenetic-based markers for molecular detection of urological cancers", Vera L. Marques Costa (ICBAS-University of Porto), awarded with a grant from FCT (SFRH/BD/23374/2005 (Public defense in 12/2010 ICBAS-University of Porto).
2.2. **Co-supervisor of the Ph.D. project** "Expression changes of the ETS family of transcription factors associated with chromosome rearrangements in breast cancer", Bárbara Alexandra de Sousa Mesquita (ICBAS-University of Porto), awarded with a grant from FCT (SFRH/BD/30097/2006)
2.3. **Co-supervisor of the Ph.D. project** "Fusion oncogenes involving the ETS family of transcription factors in prostate cancer: target genes and clinical applications", Paula Cristina Martins dos Santos Paulo (ICBAS-University of Porto), awarded with a grant from FCT (SFRH/BD/27669/2006)

2.4. **Supervisor of the Ph.D. project** "Genomic and phenotypic effects of the combined use of epigenetic-modifying drugs in prostate cancer", Maria Inês Pinho dos Santos Graça (ICBAS-University of Porto), awarded with a grant from FCT (SFRH/BD/64082/2009) – Pathology & Molecular Genetics Program.

2.5. **Supervisor of the M.Sc. project** "Epigenetic and functional characterization of *OPCML* gene in bladder carcinoma", Sara Duarte-Pereira (Public defense in 12/2009, FC/ICBAS-University of Porto).

2.6. **Supervisor of the M.Sc. project** "Prognostic value of methylation markers in breast cancer", Ana Teresa Pinto Teixeira Martins (Public defense in 12/2009, ICBAS-University of Porto).

2.7. **Co-Supervisor of the M.Sc**. **project** "Functional and epigenetic characterization of *KTN19* in renal neoplasms", Filipa Loureiro Paiva (Public defense in 12/2009, FC/ICBAS-University of Porto).

2.8. **Supervisor of the M.Sc. project** "Epigenetic and genetic alterations of *DYPD* are not predictive of severe toxicity to 5 fluorouracil-based chemotherapy in gastrointestinal cancer", Joana Savva Bordalo e Sá (Public defense in 04/2010, FM-University of Porto).

3. RESEARCH PROJECTS

3.1. "Detecção de Micrometastização Hematogénea em Doentes com Cancro da Próstata (Detection of Hematological Micrometastization in Prostate Cancer Patients)", funded by the Ministry of Health (Project no.136/95), PI: Rui Henrique, M.D.
3.2. "Estudo da Expressão das Moléculas de Adesão Celular na Biopatologia de Neoplasias Urogenitais e sua Aplicação Clínica (Study of expression of cellular adhesion molecules in Urogenital neoplasms and its clinical applications", funded by the Ministry of Health (Project no.135/95), PI: Rui Henrique, M.D.
3.3. "Pesquisa de mutações da TP53 em carcinomas uroteliais da bexiga"(Screening of TP53 mutations in urothelial, funded by the Ministry of Health (Project no. 279/97), PI: Jorge Oliveira, M.D.
3.4. "Estudo de Marcadores Biológicos de Progressão Tumoral em Melanoma Maligno Cutâneo (Study of biological markers in tumoral progression in Cutaneous Malignant Melanoma", funded by the Ministry of Health (Project no. 74/97), PI: Rui Henrique, M.D.
3.5. "Análise por hibridização comparativa do genoma em biópsias de sextante em indivíduos suspeitos de cancro da próstata (Comparative Genomic Hybridization analysis of sextant biopsies of prostatic

cancer suspects ", funded by the Ministry of Health (Project no. 219/2001), PI: Manuel Teixeira, M.D., Ph.D.

3.6. "Alterações epigenéticas em carcinoma da próstata: aplicação clínica e diagnostica (Epigenetic alterations in prostate cancer: diagnostic and clinical application)", funded by the Ministry of Health (Project no. 220/2001), PI: Jorge Oliveira, M.D.

3.7. "Diagnostic and prognostic value of cytogenetic and molecular genetic analyses of sextant biopsies from prostate cancer suspects", funded by Fundação para a Ciência e Tecnologia (Technology and Science Foundation) (Project no. POCTI/CBO/38853/2001), PI: Manuel Teixeira, M.D., Ph.D.

3.8. "Detection of neoplastic cells using DNA based technologies in clinical samples obtained by no or minimally invasive methods", funded by Fundação para a Ciência e Tecnologia (Technology and Science Foundation) (Project Plurianual no. 03/05), PI: Carmen Jerónimo, Ph.D.

3.9. "Molecular mecanisms and target genes of new cytogenetic classification of renal tumors", funded by Fundação para a Ciência e Tecnologia (Technology and Science Foundation) (Project Plurianual no. 03/05), PI: Manuel Teixeira, M.D., Ph.D.

3.10. "Identification of target genes of genomic deletions and amplifications common to breast and prostate cancer", funded by Fundação para a Ciência e Tecnologia (Technology and Science Foundation) (Project nº POCTI/SAU-OBS/58357/2004), PI: Manuel Teixeira, M.D., Ph.D.

3.11. "Characterization of fusion oncogenes involving the ETS family of transcription factors and their role as diagnostic and prognostic markers in prostate cancer", funded by Fundação para a Ciência e Tecnologia (Technology and Science Foundation) (PTDC/SAUI-OBD/70543/2006), PI: Manuel Teixeira, M.D., Ph.D.

3.12. "Avaliação do potencial clínico de biomarcadores genéticos e epigenéticos em adenocarcionma da próstata (Evaluation of the clinical potential of genetic nad epigenetic biomarkers in prostate cancer)" funded by Portuguese League Against Cancer - North, PI: Carmen Jerónimo, Ph.D. & Rui Henrique, M.D., Ph.D (2006-2009).

3.13. "Hipermetilação da região promotora do gene DLC-1 em adenocarcionama da próstata (Hipermethylation of the promoter region of DLC-1 in prostate adenocarcinoma ", funded by the Ministry of Health (Project nº 23/2007), PI: Jorge Oliveira, MD.

3.14. "Assinatura epigenética dos tumores renais: aplicação diagnóstica e clínica (Epigenetic signature of renal tumors: diagnostic and clinical application", funded by the Ministry of Health (Project nº 24/2007), PI: Francisco Lobo, MD.

3.15. "Alterações epigenéticas em genes reguladores do ciclo celular no carcinoma da próstata: implicações funcionais e potencial clínico (Epigenetic alterations of cell cycle regulator genes in prostate carcinoma: funcional and clinical potencial)", funded by the Ministry of Health (Project nº 25/2007), PI: Rui Henrique, MD,PhD

3.16. "Desenvolvimento de marcadores epigenéticos para a detecção de carcinoma da mama em biopsias aspirativas (Development of epigenetic markers for breast cancer detection in aspirative biopsies)", funded by the Ministry of Health (Project nº 21/2007), PI: Paula Monteiro, MD.

3.17. "Molecular detection of urological tumors: development of new epigenetic markers for clinical implementation", funded by the Research Centre of Portuguese Oncology Institute (CI-IPOP-4), PI: Carmen Jerónimo, PhD (2008-2010).

3.18. Project Gulbenkian 96474: Screening for urological neoplasias by new epigenetic biomarkers; Principal Investigator: Carmen Jerónimo; Funding agency: Calouste Gulbenkian Foundation; Budget: 50.000 € (2008-2010).

3.19. Project EpiDiaCan: Development of sensitive methodologies for exploitation of early epigenetic marker diagnosis in major types of cancer; Principal Investigator at IPO: Carmen Jerónimo; EU Coordinator: Alex Pintzas; Funding agency: EU. FP7-HEALTH-2009; Budget: 660.000 € (2010-2012).

PUBLICATIONS

THESIS & BOOK CHAPTERS

1. **Jerónimo C**, Master in Science Thesis:"Transitional cell carcinoma of the Bladder: expression of p53, bcl-2, nm23, CD44s, CD44v6, and BL2-10D1 and their relation to histologic grade and stage", Porto,1998.
2. **Jerónimo C,** Doctoral Thesis:"Molecular detection of prostate cancer", Porto, 2001.
3. **Jerónimo C**, Henrique R, Sidransky D. *Uses of DNA methylation in cancer diagnosis and risk assessment.* In M. Esteller (ed.): DNA methylation: approaches, methods and applications. CRC Press, Boca Raton, FL, pp. 11-26, 2004.
4. Henrique R & **Jerónimo C.** *GSTP1 hypermethylation for prostate cancer detection.* In: Thompson IM, Ankerst DP, Tangen CM (ed.): Prostate Cancer Screening Vol. II. Humana Press, Totowa, NJ, In Press.

PUBLICATIONS IN PEER REVIEWED SCIENTIFIC JOURNALS

1. **Jerónimo C**, Henrique R, Medeiros R, Santos L, Silva C, Bento MJ, Oliveira J, Carvalho R, Lopes C. Expression Of p53, bcl-2, nm23, CD44s, CD44v6, and BL2-10D1 and their relation to histologic grade and stage in transitional cell carcinoma. **J Urol Pathol.** 10: 189-205, 1999.

2. Leong PM, Kauffman CL, Moresi JM, Wu L, **Jerónimo C**, Sidransky D, Miller SJ. Epidermal basal cell carcinoma overlying dermatofibromas often reveal loss of heterozygosity in the PTCH. **J Invest Dermatol** 113(2): 279-289, 1999.

3. Henrique R, Azevedo R, Bento MJ, Domingues JC, Silva C, **Jerónimo C**. Prognostic value of Ki-67 expression in localized cutaneous malignant melanoma. **J Am Acad Dermatol** 43: 991-1000, 2000.

4. Spafford MF, Koch WM, Reed AL, Califano J, Xu LH, Eisenberger CF, Yip L, Leong PL, Wu L, Liu SX, **Jerónimo C**, Westra WB, Sidransky D. Detection of head and neck squamous cell carcinoma among exfoliated oral mucosal cells by microsatellite analysis. **Clin Cancer Res** 7(3): 607-12, 2001.

5. **Jerónimo C**, Nomoto S, Caballero O, Usadel H, Henrique R, Varzim G, Oliveira J, Lopes C, Fliss M, Sidransky D. Mitochondrial mutations in early stage prostate cancer and bodily fluids. **Oncogene** 20: 5195-5198, 2001.

6. Cairns P, Esteller M, Herman JG, Schoenberg M, **Jerónimo C**, Sanchez-Cespedes M, Chow NH, Grasso M, Wu L, Westra WH, Sidransky D. Molecular detection of early stage prostate cancer in urine. **Clin Cancer Res** 7(9): 2727-30, 2001.

7. Sanchez-Cespedes M, Parrella P, Nomoto S, Cohen D, Xiao Y, Esteller M, **Jerónimo C**, Nicol T, Koch W, Schoenberg M, Yang S. Facio VM, Giai M, Sidransky D. A specific mononucleotide repeat is the major target for frameshift mutations in mitochondrial DNA from human tumors. **Cancer Res** 61(19): 7015-9, 2001.

8. **Jerónimo C**, Usadel H, Henrique R, Oliveira J, Lopes C, Nelson WG, Sidransky D. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ confined prostate adenocarcinoma. **J Natl Cancer Inst** 93(22): 1747-52, 2001.

9. Usadel H, Brabender J, Danenberg KD, **Jerónimo C**, Harden S, Engles J, Danenberg PV, Yang S, Sidransky D. Quantitative APC-Promoter methylation analysis in tumor tissue, serum and plasma DNA of patients with lung cancer. **Cancer Res** 62(2): 371-5, 2001.

10. **Jerónimo C**, Varzim G, Henrique R, Oliveira J, Bento MJ, Silva C, Lopes C, Sidransky D. I105V polymorphism and promoter methylation of GSTP1 gene in prostate adenocarcinoma. **Cancer Epidemiol Biomark Prev** 11(5): 445-50, 2002.

11. **Jerónimo C**, Usadel H, Henrique R, Silva C, Oliveira J, Lopes C, Sidransky D. Quantitative GSTP1 hypermethylation in bodily fluids of prostate cancer patients. **Urology** 60: 1131-1135, 2002
12. **Jerónimo C**, Henrique R, Campos PF, Oliveira J, Caballero OL, Lopes C, Sidransky D. Endothelin B receptor gene hypermethylation in prostate adenocarcinoma. **J Clin Pathol** 56: 52-55, 2003
13. **Jerónimo C**, Costa I, Martins MC, Monteiro P, Lisboa S, Sousa CP, Henrique R, Teixeira MR, Lopes C. Detection of gene promoter hypermethylation in fine needle washings from breast lesions. **Clin Cancer Res** 9: 3413-3417, 2003
14. Tokumaru Y, Nomoto S, **Jerónimo C**, Henrique R, Harden S, Trink B, Sidransky D. Promoter hypermethylation is a major mechanism in inactivating the RIZ1 gene in human gastric cancer. **Oncogene** 22: 6954-6958, 2003
15. Reesink-Peters N, Wisman GB, **Jerónimo C**, Tokumaru Y, Cohen Y, Dong SM, Klip HG, Buikema HJ, Suurmeijer AJ, Hollema H, Boezer HM, Sidransky D, van der Zee AG. Detecting cervical cancer by quantitative promoter hypermethylation assay in cervical scrapings: a feasibility study. **Mol Cancer Res** 2 (5): 289-295, 2004
16. **Jerónimo C***, Henrique R*, Hoque MO, Ribeiro FR, Oliveira J, Fonseca D, Teixeira MR, Lopes C, Sidransky D. Quantitative RARβ2 hypermethylation: a promising prostate cancer marker. **Clin Cancer Research** 10: 4010-4014, 2004
17. **Jerónimo C***, Henrique R*, Oliveira J, Lobo F, Pais I, Teixeira MR, Lopes C. Aberrant Cellular Retinol-Binding-Protein 1 (CRBP1) gene expression and promoter methylation in prostate adenocarcinoma. **J Clin Pathol** 57(8): 872-6, 2004
18. Hoque MO, Begum S, Topaloglu O, **Jerónimo C**, Mambo E, Westra WH, Califano III JA, Sidransky D. Detection of promoter hypermethylation of multiple genes in the tumor, urine and serum of patients with renal cancer. **Cancer Res** 64(15): 5511-7, 2004
19. Henrique R, **Jerónimo C**. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. **Eur Urol** 46(5): 660-669, 2004
20. **Jerónimo C***, Henrique R*, Hoque MO, Mambo E, Ribeiro FR, Varzim G, Oliveira J, Teixeira MR, Lopes C, Sidransky D. A quantitative promoter methylation profile of prostate cancer. **Clin Cancer Res** 10(24): 8472-8478, 2004
21. Henrique R*, **Jerónimo C***, Hoque MO, Carvalho AL, Oliveira J, Teixeira MR, Lopes C, Sidransky D. Frequent 14-3-3σ promoter methylation in benign and malignant prostate lesions. **DNA Cell Biol** 24(4): 264-269, 2005
22. **Jerónimo C.** Quantitative methylation profiling of renal tumors and the discovery of a new generation of molecular markers. **Future Oncol** 1(2): 197-200, 2005
23. Henrique R*, **Jerónimo C***, Hoque MO, Carvalho AL, Costa VL, Oliveira J, Teixeira MR, Lopes C, Sidransky D. MT1G hypermethylation is associated with higher tumor stage in prostate cancer. **Cancer Epidemiol Biomarkers Prev** 14(5): 1274-1278, 2005.
24. Paredes J, Albergaria A, Oliveira JT, **Jerónimo C**, Milanezi F, Schmitt FC. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. **Clin Cancer Res** 11(16):5869-77, 2005.
25. Henrique R*, **Jerónimo C***, Teixeira MR, Hoque MO, Carvalho AL, Pais I, Ribeiro FR, Oliveira J, Lopes C, Sidransky D. Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. **Mol Cancer Res** 4(1):1-8, 2006.

26. Ribeiro FR, Diep CB, **Jerónimo C**, Henrique R, Lopes C, Eknaes M, Lingjaerde OC, Lothe RA, Teixeira MR. Statistical dissection of genetic pathways involved in prostate carcinogenesis. **Genes Chromosomes Cancer** 45(2):154-163, 2006.

27. Ribeiro FR, **Jerónimo C**, Henrique R, Fonseca D, Oliveira J, Lothe RA, Teixeira MR. 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects. **Clin Cancer Res** 12(13):3961-70, 2006.

28. Hoque MO, Feng Q, Toure P, Dem A, Critchlow CW, Hawes SE, Wood T, **Jerónimo C**, Rosenbaum E, Stern J, Yu M, Trink B, Kiviat NB, Sidransky D. Detection of Aberrant Methylation of Four Genes in Plasma DNA for the Detection of Breast Cancer. **J Clin Oncol** 24: 24(26): 4262-9, 2006.

29. Pinto C, Veiga I, Pinheiro M, Mesquita B, **Jerónimo C**, Sousa O, Fragoso M, Santos L, Moreira-Dias L, Baptista M, Lopes C, Castedo S, Teixeira MR. *MSH6* germline mutations in early-onset colorectal cancer patients without family history of the disease. **Br J Cancer**, 95(6): 752-756, 2006.

30. Ribeiro FR, Henrique R, Hektoen M, Berg M, **Jerónimo C**, Teixeira MR, Lothe RA. Genomic profiling of primary prostate carcinomas: novel amplified loci, recurrent regions of homozygous deletion, and methodological considerations regarding automated array-CGH scoring approaches. **Mol Cancer**, 5: 33, 2006.

31. Henrique R, Costa VL, Cerveira N, Carvalho AL, Hoque MO, Ribeiro FR, Oliveira J, Teixeira MR, Sidransky D, **Jerónimo C.** Hypermethylation of Cyclin D2 is associated with loss of expression and tumor progression in prostate cancer. **J Mol Med** 84:911-918, 2006.

32. Carvalho AL, Chuang A, Jiang WW, Lee J, Begum S, Poeta L, Zhao M, **Jerónimo C**, Henrique R, Nayak CS, Park HML, Brait MRO, Liu C, Zhou S, Koch W, Fazio VM, Ratovitski E, Trink B, Sidransky D, Moon C, Califano JA. DCC is a putative conditional tumor suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma. **Cancer Res** 66:9401-9406, 2006.

33. Cerveira N, Ribeiro FR, Peixoto A, Costa VL, Henrique R, **Jerónimo C**, Teixeira MR. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. **Neoplasia** 8:826-832, 2006.

34. Costa VL, Henrique R, **Jerónimo C**. Epigenetic markers for molecular detection of prostate cancer. **Dis Markers** 23:31-41, 2007.

35. Ribeiro FR, Henrique R, Martins AT, **Jerónimo C**, Teixeira MR. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor in prostate cancer patients. **Eur Urol** 52(1):116-25, 2007.

36. Pinto M, Soares MJ, Cerveira N, Henrique R, Ribeiro FR, Oliveira J, **Jerónimo C**, Teixeira MR. Expression changes of the MAD mitotic checkpoint gene family in renal cell carcinomas characterized by numerical chromosome changes. **Virchows Arch** 450(4):379-85, 2007.

37. Nayak CS, Carvalho AL, Jeronimo C, Henrique R, Kim MM, Hoque MO, Chang S,Jiang WW, Koch W, Westra W, Sidransky D, Califano J. Positive Correlation of Tissue Inhibitor of Metalloproteinase-3 and Death-Associated Protein Kinase Hypermethylation in Head and Neck Squamous Cell Carcinoma. Laryngoscope 117(8):1376-80, 2007.

38. Liu JW, Kim MS, Nagpal J, Yamashita K, Poeta L, Chang X, Lee J, Park HL, Jeronimo C, Westra WH, Mori M, Moon C, Trink B, Sidransky D. Quantitative hypermethylation of NMDAR2B in human gastric cancer. Int J Cancer. 121(9):1994-2000, 2007.

39. Costa VL, Henrique R, Ribeiro FR, Pinto M, Oliveira J, Lobo F, Teixeira MR, **Jerónimo C**. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. ***BMC Cancer*** 7:133, 2007.

40. Henrique R, Ribeiro FR, Fonseca D, Hoque MO, Carvalho AL, Costa VL, Pinto M, Oliveira J, Teixeira MR, Sidransky D, **Jerónimo C**. High Promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. **Clin Cancer Res** 13:6122 -6129, 2007.

41. Henrique R, Costa VL, **Jeronimo C**. Methylation based biomarkers for early detection of urological cancer. **Crit Rev Oncogenesis** 13(4):265-282, 2007.

42. Carvalho AL, **Jeronimo C**, Kim MM, Henrique R, Zhang Z, Hoque MO, Chang S, Brait M, Nayak CS, Jiang WW, Claybourne Q, Tokumaru Y, Lee J, Goldenberg D, Garrett-Mayer E, Goodman S, Moon CS, Koch W, Westra WH, Sidransky D, Califano JA. Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. **Clin Cancer Res** 14(1):97-107, 2008.

43. Hoque MO, Begum S, Brait M, **Jeronimo C**, Zahurak M, Ostrow KL, Rosenbaum E, Trock B, Westra WH, Schoenberg M, Goodman SN, Sidransky D. Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer. **J Urol** 179(2):743-47, 2008.

44. Liu JW, Nagpal JK, **Jeronimo C**, Lee JE, Henrique R, Kim MS, Ostrow KL, Yamashita K, van Criekinge V, Wu G, Moon CS, Trink B, Sidransky D. Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer. **Prostate** 68(4):418-26, 2008.

45. Hoque MO, Kim MS, Ostrow KL, Liu J, Wisman GB, Park HL, Poeta ML, **Jeronimo C**, Henrique R, Lendvai A, Schuuring E, Begum S, Rosenbaum E, Ongenaert M, Yamashita K, Califano J, Westra W, van der Zee AG, Van Criekinge W, Sidransky D. Genome-wide promoter analysis uncovers portions of the cancer methylome. **Cancer Res** 68(8):2661-70, 2008.

46. **Jerónimo C**, Monteiro P, Henrique R, Dinis-Ribeiro M, Costa I, Costa VL, Filipe L, Carvalho AL, Hoque MO, Pais I, Leal C, Teixeira MR, Sidransky D. Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. **Breast Cancer Res Treat** 109(1):27-34, 2008.

47. Liu J-W, Nagpal J, Sun W, Lee J, Kim M, Ostrow K, Zhou S, **Jeronimo C**, Henrique R, van Criekinge W, Moon C, Califano J, Trink B, Sidransky D. SSBP2 is frequently hypermethylated and suppresses cell growth in human prostate cancer. **Clin Cancer Res** 14(12):3754-60, 2008.

48. Pinto M, Vieira J, Ribeiro FR, Soares MJ, Henrique R, Oliveira J, **Jerónimo C**,Teixeira MR. Overexpression of the mitotic checkpoint genes BUB1 and BUBR1 is associated with genomic complexity in clear cell kidney carcinomas. **Cell Oncol** 30(5):389-95, 2008.

49. Soares MJ, Pinto M, Henrique R, Vieira J, Cerveira N, Peixoto A, Martins A, Oliveira J, **Jerónimo C**, Teixeira MR. CSF1R copy number changes, point mutations and RNA and protein overexpression in renal cell carcinomas. **Mod Pathol** 22:744-752, 2009.

50. Carvalho M, Ferreira PJ, Mendes VS, Silva R, Pereira JA, **Jerónimo C**, Silva MB. Human cancer cell antiproliferative and antioxidant activities of Juglans regia L. **Food Chem Toxicol** 48(1):441-750, 2010.

51. Carvalho JR, Filipe L, Costa VL, Ribeiro FR, Martins AT, Teixeira MR, **Jerónimo C**, Henrique R. Detailed analysis of expression and promoter methylation status of apoptosis-related genes in prostate cancer. **Apoptosis** 15(8):956-65, 2010.

52. Costa V L, Henrique R, Ribeiro FR, Carvalho JR, Oliveira J, Lobo F,. Teixeira MR, **Jerónimo C**. Epigenetic regulation of Wnt-signaling pathway in urological tumors. **Epigenetics** 16;5(4):343-51, 2010.

53. Vieira J, Henrique R, Ribeiro FR, Barros-Silva JD, Peixoto A, Santos C, Pinheiro M, Costa VL, Soares MJ, Oliveira J, **Jerónimo C**, Teixeira MR. Feasibility of differential diagnosis of kidney tumors by comparative genomic hybridization of fine needle aspiration biopsies. **Genes Chromosomes Cancer** 49(10):935-47, 2010.

54. Savva-Bordalo J, Ramalho-Carvalho J, Costa V L, Rodrigues A, Dias C P, Veiga I, Machado M, Teixeira MR, Henrique R, Jerónimo C. Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients **BMC Cancer** 10:470, 2010.

55. Jerónimo C, Esteller M. DNA Methylation Markers for Prostate Cancer with a Stem Cell Twist. **Cancer Prev Res** (Phila Pa) 3(9):1053-5, 2010.

56. Martins AT, Monteiro P, Ramalho-Carvalho J, Costa VL, Dinis-Ribeiro M, Leal C, Henrique R, **Jerónimo C**. High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions. **Breast Cancer Res Treat** 2010 Sep 15 [Epub ahead of print]

57. Paiva F, Duarte-Pereira S, Carvalho JR, Costa VL, Patrício P, Ribeiro FR, Lobo F, **Jerónimo C**, Henrique R. Functional and epigenetic characterization of KRT19 GENE in renal neoplasms. **DNA Cell Biol** 2010 Sep 28. [Epub ahead of print]

58. Costa VL, Henrique R, Danielsen SA, Duarte-Pereira S, Eknaes M, Skotheim RI, Rodrigues A, Magalhães JS, Oliveira J, Lothe RA, Teixeira MR, **Jeronimo C***, Lind GE*.Three epigenetic biomarkers, GDF15, TMEFF2 and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res 2010 Oct 25. [Epub ahead of print] (*should be regarded as joint senior authors).

59. Duarte-Pereira S, Paiva F, Costa VL, Ramalho-Carvalho J, Savva-Bordalo J, Rodrigues A, Ribeiro FR, Silva VM, Oliveira J, Henrique R, **Jerónimo C**. Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma. Eur J Cancer. 2011 Jan 25. [Epub ahead of print]

.

PARTICIPATION IN SCIENTIFIC MEETINGS

ORAL COMMUNICATIONS BY INVITATION

1. 9th National Conference of Medical Oncology. Espinho (Portugal). February 7-9, 2001; Title: "Molecular detection of prostate cancer Abstract published: Archives of Medicine, 15 (Supl. 1), 2001.
2. 10th National Meetings of Medical Oncology. Espinho (Portugal). 30, January 31 - February 1, 2002; Title: "Molecular biology in diagnosis of prostate cancer" Abstract published: Archives of Medicine, 16 (Supl. 1), 2002.
3. IX National Congress of Pathology. Luso (Portugal). April 22-24, 2004; Title: "Molecular detection of prostate cancer: a role for epigenetics".
4. XIV Congress of the Portuguese Society of Cytology and XVII Congreso Nacional de la Sociedad Española de Cytology. Évora (Portugal) June 1-3, 2006; Title: "Detection of epigenetic changes in the diagnostic approach of breast lesions by aspiration cytology biopsy".
5. Exploring molecular approaches to cancer research, Department of Biology, University of Minho. Braga (Portugal) 1-4 May, 2007; Title: "The role of epigenetics in neoplastic transformation".
6. GABBA Symposium-EPIGENETICS: The Emperor's New Clothes. IPATIMUP, Porto (Portugal) June, 15 , 2007; Title: “Introduction to Epigenetics” .
7. VII National Congress of Senology. Vilamoura (Portugal) 14-17 November, 2009; Title: "Epigenetics in breast cancer: reality and applications ".
8. III Technical Symposium of Pathology: Genomics, Proteomics & Environment. Great Auditorium of the Instituto Superior de Engenharia do Porto, Porto (Portugal) 12, 13 March 2010; Title: "epigenetic alterations in cancer "

ORGANIZATION OF SCIENTIFIC MEETINGS

1. "Cutaneous melanocytic lesions (melanocytic Cutaneous Lesions), Portuguese Institute of Oncology Francisco Gentil - Centro Regional do Porto, Porto, 14 th-15th of November, 1996.
2. IV Symposium of Clinical Analysis and Public Health, University Fernando Pessoa: "CANCER - Prevention, Diagnosis and Monitoring (Symposium IV of Clinical Pathology and Public Health of University Fernando Pessoa: CANCER - Prevention, Diagnosis and monitorization, Porto, 25 th of October, 2006
3. V Symposium of Clinical Analysis and Public Health, University Fernando Pessoa: "Hematologic Diseases - From Diagnosis to Therapy (V Symposium of Clinical Pathology and Public Health of University Fernando Pessoa: Haematological Diseases-From diagnosis to Therapeutics, Porto, 17th of October, 2007.

ABSTRACTS IN SCIENTIFIC JOURNALS (Selected)

1. Lopes C, Henrique R, Medeiros R, **Jerónimo C**, Silva R.XVI European Congress of Pathology. Maastricht, The Netherlands, "Expression of bcl-2, p53, nm23 and CD44s in Prostate Cancer": **Pathol Res Pract**, 193: 357, 1997.
2. Medeiros R, **Jerónimo C**, Oliveira J, Lisboa S, Henrique R, Carvalho R, and Lopes C. 31st Annual Meeting of the European Society of Human Genetics. Geneve, Switzerland, "Determination of the allelic profile of BAT26, an indicator of replication error phenotype in urological tumors": **Eur J Human Genetics**, 7: 88, 1999.
3. Lopes C, **Jerónimo C**, Nomoto S, Caballero O, Usadel H, Henrique R, Varzim G, Oliveira J, Fliss M, Sidransky D. 18th European Congress of Pathology. Berlin, Germany, "Mitochondrial mutations in early stage prostate cancer and bodily fluids": **Virchows Archiv**, 439:402, 2001.
4. **Jerónimo C**, Henrique R, Campos PF, Oliveira J, Caballero OL, Lopes C, Sidransky D. XXIV International Congress of the International Academy of Pathology. Amsterdam, The Netherlands, "Endothelin B receptor gene hypermethylation in prostate adenocarcinoma": **Histopathology**, 41:100, 2002.
5. Monteiro P, **Jerónimo C**, Henrique R, Carvalho AL, Hoque MO, Pais I, Leal C, Lopes C, Teixeira MR, Sidransky D. 94th Annual Meeting of the United States and Canadian Academy of Pathology, San António, TX, "Aberrant promoter methylation profiling of breast cancer using quantitative methylation-specific PCR": **Mod Pathol**, 18: 44A, 2005.

SCIENTIFIC ADVISORY POSITIONS

MANUSCRIPT REVIEWER (2001-current)

1. Annals of Oncology
2. Biotechniques;
3. BMC Cancer;
4. BMC Urology;
5. British Journal of Cancer;
6. Cancer Letters;
7. Cancer Research
8. Cell Proliferation;
9. Clinical Cancer Research;
10. Clinica Chimica Acta;
11. Epigenetics;
12. Epigenomics

13. Future Drugs;
14. Future Oncology;
15. Genes Chromosomes & Cancer;
16. International Journal of Cancer;
17. Journal of Biomedicine and Biotechnology;
18. Journal of Cancer Research and Clinical Oncology;
19. Journal of Clinical Pathology;
20. Journal of Molecular Medicine;
21. Journal of Urology;
22. Lancet Oncology;
23. Molecular Cancer;
24. Molecular Carcinogenesis;
25. Neoplasia;
26. Oncogene;
27. Oncology;
28. Pediatric Research;
29. Pharmacogenetics & pharmacogenomics;
30. Urology.

GRANT REVIEWER

2003 - Medical and Health Services Research Division, Health Research Board, Dublin, Ireland.
2006 - Italian Association for Cancer Research
2006 & 2007- National Medical Research Council – Singapore
2007- Cancer Research of United Kingdom
2010- Binational Science Foundation USA-Israel

HONORS & AWARDS

1. Prize "AACR-AstraZeneca Scholar-in-Training Award" at the "95th American Association for Cancer Research (AACR) Meeting", Orlando, Florida (USA), 2004; Oral Communication: "Detection of promoter hypermethylation of multiple genes in the tumor, urine and serum of Patients with renal cancer", Hoque MO, Begum S, Topaloglu O, Jeronimo C, Mambo E, Westra WH, Califano JA III, Sidransky D.
2. 2nd Prize for the best oral communication (ex aequo) in the category of "Basic Research" presented at the Seminar of the Department of Medical Oncology, Espinho, January, 2006; "Epigenetic heterogeneity in lesions of PIN (prostatic intraepithelial neoplasia): evidence of clonal progression in prostate carcinogenesis" Henrique R, Jerónimo C, Teixeira MR, Hoque MO, Carvalho AL, Pais I, Ribeiro FR, Oliveira J, Lopes C, Sidransky D.
3. 1 st Honorable Mention LabMED 2005; Scientific paper: "8q Gain Is an Independent Predictor of Poor Survival in Diagnostic Needle Biopsies from Prostate Cancer Suspects," Franclim R. Ribeiro, Carmen Jerónimo, Rui Henrique, Daniel Fonseca, Jorge Oliveira, Ragnhild A. Lothe, and Manuel Teixeira
4. Prize for the best oral communication in the category of "Basic Research" presented at the Seminar of the Department of Medical Oncology, Espinho, May, 2007;"Epigenetic markers increase the diagnostic accuracy of aspiration cytology of breast lesions". Jerónimo C, Miller P,

Henry R, Dinis-Ribeiro M, Costa I, Costa VL, Philip L, Carvalho AL, Hoque MO, Pais I, C Leal, Teixeira MR, Sidransky D.

5. Prize for the best poster presented at the Congress XII National Congress of Pathology & Eleventh Meeting of the Portuguese Society of Cytology. Thursday tears Coimbra, 3-5 May, 2007; "Quantitative analysis of promoter methylation of multiple genes involved in renal carcinogens" Henrique R, Costa VL, RibeiroFR, Pinto M, Oliveira J, Lobo F, Teixeira MR, Jerónimo C.
6. 1 st Honorable Mention LabMED 2006: Scientific paper: "TMPRSS2-ERG gene fusion Causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions" by Cerveira N, Ribeiro FR, Peixoto A, Costa VL, Henrique R, Jerónimo C, Teixeira MR.
7. 2nd Honorable Mention LabMED 2006: Scientific paper: "Hypermethylation of Cyclin D2 Is Associated with loss of expression and tumor progression in prostate cancer" by Henrique R, Costa VL, Cerveira N, Carvalho AL, Hoque MO, Ribeiro FR, Oliveira J, Teixeira MR, Sidransky D, Jerónimo C.

SCIENTIFIC ASSOCIATION MEMBERSHIPS

1992 – current: Portuguese Biologists Association (OB, Ordem dos Biólogos)
1999 – current: American Association for Cancer Research (AACR)
2000 – current: Portuguese Society of Human Genetics (SPGH, Sociedade Portuguesa de Genética Humana)
2002 – current: European Association for Cancer Research (EACR)

LINKS

- Personel Webpage

URL:http://publicationslist.org/carmenjeronimo

- Research Center of Portuguese Oncology Institute-Porto (CI-IPOP)-Cancer Epigenetics Group

URL:http://sites.google.com/site/ipoportoresearchcenter/researchgroups/cancerepigenetics

- Research Center of Portuguese Oncology Institute-Porto (CI-IPOP)

URL:http://sites.google.com/site/ipoportoresearchcenter/Homepage

- Institute of Biomedical Sciences Abel Salazar (ICBAS) University of Porto

  URL: http://www.icbas.up.pt